Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04740-9 As presented at the ESMO Congress 2026: In this exploratory, nonrandomized phase 2a trial, treatment of patients with immune checkpoint inhibitor-naive muscle-invasive bladder cancer with the GDF-15-neutralizing antibody visugromab and nivolumab produced encouraging pathological complete response and radiographic…

nature.com ·10h ago

We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.

Read the original at nature.com →

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

More in Health & Medicine

Lung cancer drug some Americans fly to China to buy is now on sale in US

Kenya: 'Burden and Loss' Builds in DR Congo, As Kenya Strengthens Ebola Containment

Kenya: 'Burden and Loss' Builds in DR Congo, As Kenya Strengthens Ebola Containment

Woman, 65, becomes second patient to die of Ebola in Kenya

Ebola Between Public Health Emergency and Constitutional Democracy Sampson Parker

Ebola vaccine trial begins in DR Congo